Patents by Inventor Benedict R. Lucchesi

Benedict R. Lucchesi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions containing contortrostatin and methods for the use thereof
    Patent number: 5731288
    Abstract: Contortrostatin is employed as active agent for treatment of thrombotic disease. Preferably, contortrostatin is employed in conjunction with at least one thrombolytic agent. In addition, contortrostatin is useful in compositions and methods for preventing metastases in carcinoma and melanoma patients, treating or preventing osteoporosis and promoting wound healing.
    Type: Grant
    Filed: April 15, 1996
    Date of Patent: March 24, 1998
    Assignee: University of Southern California
    Inventors: Francis S. Markland, Jr., Benedict R. Lucchesi, Mohit Trikha
  • Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
    Patent number: 4935234
    Abstract: A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.
    Type: Grant
    Filed: March 7, 1988
    Date of Patent: June 19, 1990
    Assignee: Dana-Farber Cancer Institute
    Inventors: Robert F. Todd, III, Paul J. Simpson, Benedict R. Lucchesi, Stuart F. Scholossman, James D. Griffin
  • Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
    Patent number: 4840793
    Abstract: A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.
    Type: Grant
    Filed: June 11, 1987
    Date of Patent: June 20, 1989
    Assignees: Dana-Farber Cancer Institute, The University of Michigan
    Inventors: Robert F. Todd, III, Benedict R. Lucchesi, Paul J. Simpson, James D. Griffin, Stuart F. Schlossman
  • 1-(Trialkylamino)-3-(phenylphenoxy)-2-propanol quarternary salts
    Patent number: 4241088
    Abstract: The above captioned compounds exhibit potent and long acting anti-arrhythmic activity while lacking the undesirable side effects, e.g. .beta.-adrenergic receptor blocking activity and local anesthetic activity, characteristic of related prior art compounds.
    Type: Grant
    Filed: March 24, 1977
    Date of Patent: December 23, 1980
    Assignee: The Regents of the University of Michigan
    Inventors: Raymond E. Counsell, Benedict R. Lucchesi
  • Method of inhibiting myocardial ischemia in mammals using quaternary salts
    Patent number: 4048335
    Abstract: 1-(N-isopropyl-N,N-dimethylamino)-3-(1-naphthoxy)propan-2-ol quaternary salts are useful cardiovascular agents as evidenced by their potent and long-acting anti-arrhythmic, anti-fibrillatory and myocardial ischemia-inhibitory activity. They, furthermore, lack the undesirable side-effects, e.g. .beta.-adrenergic receptor blocking and local anesthetic activity, characteristic of related prior art compounds.
    Type: Grant
    Filed: August 19, 1976
    Date of Patent: September 13, 1977
    Assignee: The Regents of the University of Michigan
    Inventor: Benedict R. Lucchesi
  • Novel quaternary salts and method
    Patent number: 4001327
    Abstract: 1-(N-isopropyl-N,N-dimethylamino)-3-(1-naphthoxy)propan-2-ol quaternary salts are useful cardiovascular agents as evidenced by their potent and long-acting anti-arrhythmic, anti-fibrillatory and myocardial ischemia-inhibitory activity. They, furthermore, lack the undesirable side-effects, e.g. .beta.-adrenergic receptor blocking and local anesthetic activity, characteristic of related prior art compounds.
    Type: Grant
    Filed: June 17, 1974
    Date of Patent: January 4, 1977
    Assignee: The Regents of the University of Michigan
    Inventor: Benedict R. Lucchesi